CeMM

What CeMM does

CeMM Research Center for Molecular Medicine GmbH is a Vienna-based, non-profit basic research institute founded in 2005 and wholly owned by the Austrian Academy of Sciences (ÖAW). Operating from a dedicated research building on the Medical University of Vienna and Vienna General Hospital campus, CeMM conducts post-genomic molecular medicine research aimed at understanding the molecular basis of human diseases in immunology, cancer, metabolic disorders, infections, and aging. Its research outputs span high-impact peer-reviewed publications, open-source computational tools, and a portfolio of biotech spin-offs (Cellzome, Haplogen, Allcyte, Proxygen, Solgate, Postbiotica) generated through a long-running tech-transfer program.

Name

CeMM

Legal name

CeMM Research Center for Molecular Medicine GmbH of the Austrian Academy of Sciences

Website

https://cemm.at

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

CeMM is a Vienna-based, ÖAW-owned non-profit research institute conducting post-genomic molecular medicine to elucidate human disease mechanisms, serving the international scientific community via publications, open-source AI tools, and biotech spin-offs.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Molecular medicine research
• Biomedical research institute
• Genomic sequencing services
• Drug discovery research
• Digital pathology software

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Government Funding: Primary funding from the Austrian Academy of Sciences (ÖAW), which is 100% shareholder. Core operational funding for basic research institute.
2. Research Grants: Competitive research funding including ERC Advanced Grants, Horizon Europe grants, EP PerMed grants, and other European funding programs supporting specific research projects.
3. Sponsorship and Donations: Private sponsorship and donations from individuals and organizations supporting CeMM's research and activities, including art facade sponsors and research report supporters.
4. Tech Transfer and Licensing: Technology transfer activities including patents and commercialization of research discoveries. Notable spin-offs include Cellzome, Haplogen, Allcyte, Proxygen, and Solgate (founded by Giulio Superti-Furga).

Distribution channels1 record

Marketing channels5 records

Core offering

CeMM conducts basic and biomedical molecular medicine research, operating state-of-the-art research platforms such as the Molecular Discovery Platform (MDP) and the Biomedical Sequencing Facility (BSF), and developing open-source software tools including LazySlide for AI-driven digital pathology analysis and VRNetzer for immersive molecular network visualization. Its research programs span aging, drug discovery, genomic medicine, clinical science, disease model systems, immunity, and chemistry, with results disseminated through publications, conferences, and tech transfer.

Product overview

CeMM is a basic research institute, not a commercial product company. Its offerings consist of research platforms, facilities, and open-source software tools developed by its researchers. The core research infrastructure includes the Molecular Discovery Platform (MDP) for drug discovery support, the Biomedical Sequencing Facility (BSF) for genomics services, and specialized computational tools like LazySlide for digital pathology analysis using AI. VRNetzer provides immersive visualization of molecular networks. These offerings are made available to researchers through collaborations, publications, and facility access rather than as commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• LazySlide Open-source AI-driven software tool that enables researchers to analyze whole-slide pathology images using foundation models, connects visual tissue information with molecular data such as gene expression profiles, and allows natural language queries to search tissue images. Aimed at biomedical researchers in digital pathology and computational biology.
• VRNetzer Virtual Reality Network Analysis Platform developed by Jörg Menche's group that allows researchers to dive deep into massive molecular networks behind genetic diseases using VR glasses, visualizing complex protein interaction data. Targeted at biomedical researchers studying disease networks.
• Molecular Discovery Platform (MDP) State-of-the-art CeMM research platform offering access to mass spectrometry, genomics facilities, a deep-sequencing unit, bioinformatics expertise, a chemical biology facility, a virology lab, and imaging and sorting technologies for molecular discovery research. Used by CeMM researchers and collaborators.
• Biomedical Sequencing Facility (BSF) A deep-sequencing unit and genomics facility providing next-generation sequencing services and advanced genomic analysis capabilities to biomedical researchers at and beyond CeMM.

Quantifiable outcome

• High-impact publications in leading journals including Nature Methods, Nature Chemical Biology, Nature Communications, and Cell
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• EU-LIFE AlliancecoreStrategic or Co-development Partner · 1 January 2013EU-LIFE is an alliance of leading European research institutes in life sciences. CeMM has been a proud member since its creation in 2013, actively contributing to all activities, working groups, projects, and events. CeMM Director Giulio Superti-Furga served as EU-LIFE co-chair (2022-2023) and is current chair (2024-2025). The alliance includes 17 member institutes including Babraham Institute, CRG, Francis Crick Institute, and others.
• Austrian Academy of Sciences (ÖAW)coreStrategic or Co-development PartnerThe Austrian Academy of Sciences (ÖAW) is CeMM's parent organization and 100% shareholder. Founded in 1847, ÖAW operates over 25 research institutes and provides the framework for CeMM's independent, innovative, and socially relevant biomedical research.
• Medical University of Vienna (MedUni Vienna)coreStrategic or Co-development PartnerCeMM is embedded in the campus of the Medical University of Vienna and Vienna General Hospital, Austria's largest medical research complex. Many Principal Investigators maintain daily collaborations between their medical duties and CeMM research. Several researchers hold joint positions.
• Vienna General Hospital (AKH)coreStrategic or Co-development PartnerAustria's largest medical research complex where CeMM is located, enabling close collaboration between basic researchers and clinicians working on predictive, preventive, and personalized medicine.
• AITHYRAmajorStrategic or Co-development PartnerAITHYRA is the Research Institute for Biomedical Artificial Intelligence of the Austrian Academy of Sciences, founded in 2024 in Vienna. CeMM CEO Anita Ender is CEO of AITHYRA, and together with Michael Bronstein (founding director), they secured 150 million euros in funding from Boehringer Ingelheim Stiftung.
• Humanitas University / Humanitas Research HospitalmajorStrategic or Co-development PartnerMaria Rescigno, CeMM's new Scientific Director (appointed November 2025), was previously Vice-Rector for Research and Deputy Scientific Director at Humanitas University in Milan, where she led the Immunology Program and Laboratory of Mucosal Immunology and Microbiota.
• Horizon Europe / Horizon 2020majorStrategic or Co-development PartnerCeMM participates in Horizon Europe Mission Cancer projects including PhotoMel investigating melanoma risk in young adults, and EP PerMed for personalized treatment in children. Multiple researchers are part of these European consortiums.
• St. Anna Children's Cancer Research Institute (St. Anna CCRI)majorStrategic or Co-development PartnerResearchers in the Davide Seruggia group work jointly at St. Anna CCRI and CeMM, collaborating on childhood leukemia research and other cancer studies.
• Ludwig Boltzmann GesellschaftminorStrategic or Co-development PartnerSuccessful cooperation on rare diseases through the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, and new partnership through Ludwig Boltzmann Institute for Network Medicine for research on biological organization principles.
• Max Perutz Labs / University of ViennamajorStrategic or Co-development PartnerJörg Menche, CeMM Adjunct PI, is also affiliated with Uni Vienna/Max Perutz Labs. Collaborations on molecular network research and VRNetzer platform development.
• EMBL (European Molecular Biology Laboratory)majorStrategic or Co-development PartnerGiulio Superti-Furga was a postdoctoral fellow and team leader at EMBL until 2004. Multiple collaborations with EMBL institutes continue, and Ewan Birney from EMBL-EBI serves on CeMM's Scientific Advisory Board.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CeMM_News
• LinkedInlinkedin.com/company/cemm

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CeMM